ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Drug repositioning as an antivirulence strategy: Ketoprofen targets quorum sensing and biofilm in Serratia sp.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Serratia sp. are opportunistic Gram-negative bacteria capable of forming robust biofilms and expressing a wide range of quorum sensing (QS)-regulated virulence factors, including motility, protease secretion, and prodigiosin production. The rise of multidrug-resistant strains has emphasized the urgent need for alternative therapeutic strategies targeting bacterial virulence rather than viability. In this context, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen have emerged as potential quorum-quenching agents. This study explores the antivirulence activity of ketoprofen against Serratia sp. through a combination of in-vitro phenotypic assays and an advanced in-silico framework. In-vitro assays demonstrated that sub-inhibitory concentrations of ketoprofen significantly impair key virulence traits. Ketoprofen exhibited up to 90.68% inhibition of initial bacterial adhesion and disrupted mature biofilms, reducing biomass by up to 79.1%. Furthermore, motility assays revealed profound inhibition of both swimming and swarming behaviors, alongside a 100% suppression of protease activity and a 60.4% reduction in prodigiosin production, without exerting direct bactericidal effects. To elucidate the molecular basis of this competitive antagonism, an integrative computational approach was deployed. Deep learning-driven molecular docking (GNINA) revealed that ketoprofen targets the LuxR-type QS receptor SmaR with exceptional and reproducible affinity (mean Vina affinity of -9.51 kcal/mol), vastly outperforming natural acyl-homoserine lactone (AHL) autoinducers. Kinetic stability was validated through 5 ns vacuum molecular dynamics (MD), followed by 100 ns explicit solvent MD simulations in independent replicates. The trajectories confirmed remarkable positional retention of the ligand (Ligand RMSD ~ 0.08-0.16 nm) within the binding pocket. Rigorous MM/PBSA free energy calculations on the equilibrated trajectories yielded highly favorable binding free energies (ΔG ranging from - 19.90 to -30.11 kcal/mol), driven by massive enthalpic contributions (ΔH up to -34.20 kcal/mol) and a persistent network engaging 10 to 14 key interacting residues. Overall, these findings demonstrate that ketoprofen acts as a highly stable "molecular plug", effectively outcompeting endogenous AHL signals to lock the SmaR receptor in an inactive state. This highlights ketoprofen's immense potential as a repurposed antivirulence agent for combating biofilm-associated and multidrug-resistant Serratia infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.